BRIEF published on 02/19/2026 at 10:33, 3 months 25 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
BRIEF published on 12/09/2025 at 14:55, 6 months 7 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 6 months 7 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 6 months 7 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 7 months 5 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 7 months 5 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 7 months 11 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 7 months 11 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 8 months 6 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 8 months 6 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
Published on 06/17/2026 at 00:35, 3 hours 48 minutes ago INEO Tech Corp. Announces Closing of Private Placement and Debt Settlement
Published on 06/17/2026 at 00:28, 3 hours 55 minutes ago Apex Critical Metals Announces Filing of Technical Report on the Rift Rare Earth Project
Published on 06/17/2026 at 00:10, 4 hours 13 minutes ago Panther Minerals Announces Brokered Private Placement of up to $3,000,000
Published on 06/17/2026 at 00:00, 4 hours 23 minutes ago Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
Published on 06/16/2026 at 23:10, 5 hours 13 minutes ago Crestone Air Partners, an Air T Business, Completes Acquisition of Arena Aviation Capital, Surpassing $3.6 Billion in Assets Under Management
Published on 06/17/2026 at 04:15, 8 minutes ago Frost & Sullivan White Paper Names Phancy Rise vGPU a Tier 1 Leading Platform
Published on 06/16/2026 at 19:05, 9 hours 18 minutes ago AT&S announces the Reference Share Price and the Conversion Price of the new deeply subordinated perpetual convertible bond with an early redemption option for the Company
Published on 06/16/2026 at 19:00, 9 hours 23 minutes ago R. STAHL Shareholders approve nearly all agenda items at the Annual General Meeting – Executive Board confirms annual forecast
Published on 06/16/2026 at 18:15, 10 hours 7 minutes ago SUCCESSFUL PRICING OF €900,000,000 SENIOR NOTES DUE 2033 BY BIRKENSTOCK GROUP B.V. & CO. KG AND NOTICE OF REDEMPTION OF 5.25% SENIOR NOTES DUE 2029 ISSUED BY BIRKENSTOCK FINANCING S.À R.L.
Published on 06/16/2026 at 11:44, 16 hours 38 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 5 hours ago BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 1 day 9 hours ago Reporting on share buyback transactions carried out between June 8 and June 11, 2026
Published on 06/15/2026 at 18:32, 1 day 9 hours ago Edenred strengthens its electric charging offering with the acquisition of The Mobility House Solutions
Published on 06/15/2026 at 18:30, 1 day 9 hours ago Increase in the resources allocated to the liquidity contract with ODDO BHF
